Background: PI3Kc functions in the immune compartment to promote inflammation in response to G-protein-coupled receptor (GPCR) agonists and PI3Kc also acts within the heart itself both as a negative regulator of cardiac contractility and as a pro-survival factor. Thus, PI3Kc has the potential to both promote and limit M I/R injury.
Introduction
Cardiac damage in acute myocardial infarction results from a disruption of blood flow to the heart (ischemia) that may be followed by either spontaneous or therapeutically induced restoration of blood supply (reperfusion). Myocardial ischemia/ reperfusion (M I/R) results in infarction due to intrinsic cardiomyocyte death [1, 2] and damage via excessive immune activation [3, 4, 5] . Many inflammatory factors that build up during injury exert their effects through G-protein coupled receptors (GPCRs) [6] suggesting that mediators of GPCRs might be critically involved in the M I/R damage response. One key signaling pathway downstream of GPCRs is mediated via phosphoinositide 3-kinase c (PI3Kc).
Phosphatidylinositol-3-OH kinases (PI3K) are lipid kinases that convert phosphatidylinositol 4,5-bisphosphate (PIP2) into phosphatidylinositol (3,4,5)-trisphosphate (PIP3). In mammals, there are four class I PI3K, three of which (a, b, and d) are primarily activated by tyrosine kinase signaling pathways, whereas PI3Kc is the principal PI3K that relays signals via GPCRs to downstream pathways such as AKT and ERK/1/2 [7] . PI3Kc 2/2 mice (lacking the catalytic subunit p110) are viable and in certain experimental settings exhibit reduced inflammation [8, 9] as the PI3Kc pathway controls migration of inflammatory cells [10] . In addition, we have previously shown that PI3Kc acts as an intrinsic negative regulator of cardiac contractility [11, 12] . Given its dual roles in cardiomyocyte function and inflammation, it is not clear if the net effect of PI3Kc loss is cardio-protective or cardiodestructive during M I/R. For example, we have previously shown that PI3Kc 2/2 mice are resistant to the detrimental effects of chronic b-adrenergic receptor signaling [13] . Conversely, PI3Kc 2/2 mice showed a worse outcome both in a model of chronic myocardial ischemia without reperfusion [14] and chronic pressure overload [12] , while overexpression of catalytically inactive PI3Kc protected from heart failure in this model [15] . Moreover, it has been reported that a PI3Kc blocker might protect from M I/R injury due to inhibition of the inflammatory response during reperfusion [16] . However, since such blockers are not specific for PI3Kc and PI3Kc inhibitors are currently developed as a novel treatment option for M I/R in humans, it is paramount to genetically define the role of PI3Kc in cardiac ischemia/reperfusion injury.
We therefore assessed the role of PI3Kc in M I/R injury using PI3Kc 2/2 mice. We report that PI3Kc mutant mice develop massive early and late stage cardiac M I/R injury. PI3Kc seems to be the key kinase that activates the Reperfusion Injury Salvage Kinase (RISK) pathway (AKT/ERK1/2) in the acute setting of M I/R. Using bone marrow chimeras these effects were mechanistically mapped to non-haematopoetic cells suggesting that the effects are intrinsic to cardiac tissue. To assess whether these effects are dependent on catalytic activity, we performed M I/R injury in mice with a knock-in mutation in the PI3Kc kinase domain (PI3Kc KD/KD ). PI3Kc KD/KD mice developed cardiac injury similar to wild type mice. Thus, PI3Kc protects the heart from M I/R injury through a kinase-independent mechanism in vivo.
Results

Genetic Inactivation of PI3Kc Results in Severe Cardiac Damage to M I/R Injury
To assess the role of PI3Kc in M I/R injury, we performed in vivo reversible LAD ligation in sex and age matched PI3Kc 2/2 (KO) mice and PI3Kc expressing wild type mice (WT). The extent of injury and heart functions were assayed 3 hours, 24 hours, 1 week, and 3 weeks after initiation of reperfusion. Intriguingly, in PI3Kc 2/2 mice serum Troponin T levels, a marker of cardiac damage, were significantly increased after 3 hours of reperfusion ( Figure 1A) , without a significant change in the number of inflammatory cells infiltrating the damaged cardiac tissue ( Figure 1B ). In parallel, we observed a massive increase of the infarction size within the area at risk in PI3Kc 2/2 hearts at the early stage of M I/R injury (assayed at 24 hours, Figure 1C -E). Thus, immediately after M I/R the loss of PI3Kc expression results in massive early heart damage.
It was possible that in the long term the early cardioprotective effects of PI3Kc would not outweigh secondary pro-inflammatory effects due to impaired migration of inflammatory cells into the damaged heart; therefore, the net result of disrupting PI3Kc expression could be cardioprotective. To address this possibility we performed M I/R injury on wild type (WT) and PI3Kc 2/2 (KO) mice and followed these mice for up to three weeks. One week after M I/R injury, PI3Kc 2/2 mice still exhibited a massive increase in infarction size as compared to the control cohort (Figure 2A,B) . Again we observed no significant differences in the numbers of inflammatory cells infiltrating the cardiac tissue between control and PI3Kc 2/2 mice ( Figure 2C ), suggesting that PI3Kc is not required for recruitment of inflammatory cells to the infarction site during the early (3 hours) as well as later stages (1 week) stages of M I/R injury.
Following the inflammatory phase of M I/R injury, scar formation occurs at the infarction site. In both wild type and PI3Kc 2/2 mice the primary damage site was replaced by scar tissue 3 weeks after the initial M I/R injury ( Figure 2D ). In line with the increased injury, collagen deposition and scar formation was markedly increased in PI3Kc 2/2 mice ( Figure 2D , E). We next assessed cardiac function 3 weeks after M I/R injury. Functionally, the excessive early damage and increased scar formation in M I/R injured PI3Kc 2/2 mice culminated in a severe reduction in cardiac contractility as defined by changed fractional shortening from the baseline ( Figure 2F ). Thus, PI3Kc is cardio-protective during M I/R injury and genetic disruption of PI3Kc results in severe cardiac damage that is sustained over time and severely compromises cardiac function.
PI3Kc Affects Cardiac M I/R Injury Independent of the Haematopoietic System
PI3Kc controls multiple activation pathways in haematopoetic cells including cell migration [7] and it has been proposed that PI3Kc might be a key drug target to block inflammation in various pathologic conditions including M I/R injury in heart attacks [17] . To directly test whether the protective effects of PI3Kc are due to its function in the immune system, we generated bone marrow chimeras. Interestingly, although PI3Kc has clearly been implicated in inflammation in many other systems [7] , wild type mice given either wild type or PI3Kc 2/2 bone marrow developed comparable M I/R injuries ( Figure 3A , C) and showed equal Troponin T release ( Figure 3D ). Moreover, PI3Kc 2/2 and wild type immune cells accumulated to a similar extent at the site of M I/R injury ( Figure 3E ).
In the reciprocal experiment, wild type or PI3Kc 2/2 bone marrow was transferred into PI3Kc 2/2 recipients; in these bone marrow chimeras we again observed comparable infarction sizes ( Figure 3B , C) and Troponin T release ( Figure 3D ). Irrespective of the genotype of the transferred bone marrow cells, PI3Kc 2/2 recipient mice exhibited similar inflammation at the site of infarction ( Figure 3E ). Of note, in all bone marrow transplantation experiments, PI3Kc 2/2 recipient mice developed markedly more severe cardiac damage following M I/R injury as compared to wild type host mice ( Figure 3B -D). These data indicate that the excessive damage seen in PI3Kc 2/2 mice following M I/R injury occurs independent of its role in haematopoietic cells.
Loss of PI3Kc Results in Impaired RISK Signaling
Activation of the PI3K pathway leads to cell survival through activation of the Reperfusion Injury Salvage Kinase (RISK) pathway (AKT/ERK1/2) [2, 10] . Similar to the growth factor coupled class IA PI3Ks a,b, and d, PI3Kc can relay GPCR signals to activate AKT and ERK1/2 in cardiomyocytes [11, 12, 13] . To assess AKT and ERK activation in M I/R injury, we isolated hearts from wild type and PI3Kc 2/2 mice prior to ischemia, after 30 minutes of ischemia, and 40 minutes as well as 24 hours after initiation of reperfusion. Protein extracts were isolated from the area at risk and immunoblotted for phosphorylated AKT (T308 and S473, Figure 4A ) and phosphorylated ERK1/2 (T202/Y204, Figure 4B ), both indicative of activate AKT and ERK1/2.
As previously reported [11, 13] , wild type and PI3Kc 2/2 mice exhibit comparable baseline phosphorylation of both AKT and ERK1/2. Following 30 minutes of ischemia due to in vivo LAD ligation, AKT and ERK1/2 activation were comparably reduced in both genotypes. Ischemia-induced decrease in AKT and ERK1/2 phosphorylation was rapidly restored in wild type animals within 40 minutes of reperfusion. By contrast, in PI3Kc 2/2 mice AKT and ERK1/2 phosphorylation were still markedly reduced 40 minutes after reperfusion ( Figure 4A , B). These marked differences in AKT and ERK1/2 activation were not apparent after 24 hours of reperfusion, indicating a role of PI3Kc in the early initiation of pro-survival signaling through AKT and ERK1/2. Immunohistochemical staining to detect phosphorylated AKT (S473) showed that active AKT is localized to the area at risk of wild type hearts ( Figure 4C ). Of note, in vivo M I/R did not alter the PI3Kc protein content in the early phase of reperfusion ( Figure 4D ). Thus, PI3Kc 2/2 mice fail to activate AKT and ERK1/2 immediately following M I/R injury, and this lack of activation can be localized to the area at risk. In addition to AKT and ERK1/2 activation, PI3Kc is a regulator of myocardial contractility [11] via regulation of phosphodiesterases and subsequent phospholamban (PLB) phosphorylation in the sarcoplasmatic reticulum [12, 18] . Phosphorylation of PLB results in increased contractility [11] . Confirming previous results, PI3Kc 2/2 hearts exhibit a much higher basal level of phosphorylated PLB ( Figure 4E ). Whereas in wild type hearts phosphorylated PLB was decreased following ischemia and 40 minutes of reperfusion, such decrease in phosphorylated PLB was less pronounced in ischemic PI3Kc 2/2 hearts. Moreover, as compared to wild type control mice, in PI3Kc 2/2 mice phosphorylation of PLB was restored to basal levels during the vulnerable early stage (40 minutes) of reperfusion. Thus, loss of PI3Kc results in marked dysregulation of the RISK pathway and phospholamban.
Kinase Dependency of PI3Kc during M I/R
PI3Kc exerts kinase-dependent and kinase-independent functions [12] . To address the issue of kinase dependency we subjected wild type, PI3Kc 2/2 mice, and PI3Kc kinase-dead knock-in mice (PI3Kc KD/KD ) to M I/R injury. Whereas PI3Kc 2/2 mice again exhibited severe infarction following M I/R injury, PI3Kc KD/KD mice displayed cardiac damage that was comparable to wild type control mice ( Figure 5A -E). These differences between PI3Kc 2/2 mice and PI3Kc KD/KD as well as control mice were already evident at 3 and 24 hours of reperfusion (Fig. 5A-C) . PI3Kc mice again showed severely compromised cardiac contractility and fractional shorting following M I/R injury. By contrast, the observed reduction in M I/R-induced infarction size in PI3Kc KD/KD mice translated into impaired cardiac contractility that was again comparable to that of wild type mice (Figure 5F, G) . Thus, the cardioprotective function of PI3Kc during M I/R injury appears to be independent of its kinase activity. However, PI3Kc KD/KD mice exhibited a cardiac injury similar to wild type animals.
Discussion
In the current study we surprisingly observed little requirement for PI3Kc during inflammation associated with M I/R injury. Genetic evidence has implicated PI3Kc as a proinflammatory intracellular signaling component important for neutrophil chemotaxis [8, 9] . In vivo, PI3Kc 2/2 mice have been shown defective in diverse models of inflammation, including acute peritonitis [8, 9] and delayed type hypersensitivity [19] . In addition, PI3Kc 2/2 mice develop attenuated atherosclerosis [20] . While loss of PI3Kc alone may slow neutrophil migration [21] , this loss does not appear to affect inflammation even in the early stages of our M I/R injury model. It has been shown that in vivo PI3Kc cooperates with PI3Kd to promote efficient neutrophil migration in response to chemokines and proinflammatory cytokines such as TNF-a [22] . Most importantly, our bone marrow transplantation experiments exclude a requirement for PI3Kc in cardiac inflammation following M I/R injury.
Enhanced contractility by increased PLB phosphorylation [23, 24] and/or reduced RISK signaling via AKT and ERK1/2 [2] could contribute to the severe injury phenotype we observed in PI3Kc 2/2 mice. We found that knock-in mice lacking the PI3Kc kinase activity (PI3Kc KD/KD ) display an M I/R injury phenotype that is similar to wild type animals. Therefore, the detrimental outcome observed in PI3Kc 2/2 animals appears to be due to kinase-independent events, possibly via phospholamban hyperphospholryation and hypercontractility. PI3Kc blockers have entered clinical development for chronic inflammation and heart attacks in humans [16, 25] . Our data on PI3Kc in M I/R injury suggest that specific inhibition of PI3Kc will not result in any overall improvement concerning cardiac function and the extent of injury. Moreover, we observed a loss of RISK activation in PI3Kc 2/2 mice, suggesting that treatment with PI3Kc blockers may interfere with these early pro-survival signals in some contexts. Of note, the observed loss of immediate RISK activation itself does not appear to compromise M I/R outcome in our model. These data are consistent with other recent studies questioning the cardioprotective role of RISK [26, 27] . Similar to our first in vivo evidence on M I/R injury using mutant mice and kinase-dead knock-in mice, previous work has shown that PI3Kc is an important signaling pathway that controls ischemic preconditioning in vitro [28] , arguing that if anything, strategies to activate, not inhibit, PI3Kc may improve outcome for patients with ischemic heart disease.
The present study provides evidence that PI3Kc is cardioprotective in vivo in a mouse model of myocardial ischemia/ reperfusion. Surprisingly, the severe cardiac damage observed in PI3Kc 2/2 mice occurs very rapidly and is not influenced by PI3Kc expression within the hematopoietic compartment, suggesting that PI3Kc exerts a cell autonomous protective function in cardiomyocytes. Using kinase dead knock-in mice, these detrimental effects were mapped to be independent of PI3Kc lipid kinase activity. However, loss of PI3Kc catalytic activity does not translate into a beneficial outcome but could negatively influence RISK signaling during the acute phase of reperfusion. In conclusion, our genetic data indicate that specific inhibition of PI3Kc is not cardioprotective. Therefore, treatment of acute infarctions with PI3Kc inhibitors should proceed with caution. 
Methods
Mice/Ethics Statement
Surgical Procedure and Experimental Protocol
PI3Kc 2/2 , PI3Kc KD/KD , and control mice were randomised into a three-hour, 24-hour, one-week, and three-week reperfusion groups and underwent in vivo reversible LAD ligation as described [29, 30] . Briefly, following sedation, tracheotomy, ventilation, and thoracotomy, the LAD was reversibly ligated aided by a PE tube. After 30 minutes of ischemia, the PE tube was removed and reperfusion was visually confirmed. The overall peri-and postprocedural mortality was below 10% (control mice: 5,7%; PI3Kc 2/2 : 6,1%; PI3Kc KD/KD : 9,7%).
Infarct Evaluation
Heparinized blood was collected from the retrobulbar vein plexus. Plasma levels of troponinT were evaluated as a biomarker for cardiac damage using a quantitative assay (Roche Diagnostics, Austria). Moreover, hearts were fixed in 4% formaldehyde overnight and embedded in paraffin. Three 5-mm sections were cut from defined levels of the left ventricle, stained with hematoxylin and eosin (H&E). Infarct sizes were analyzed using Axio Imager M1 (Zeiss, Axiovert, Jena, Germany) and Tissue-FAXS software package (TissueGnostics, Vienna, Austria). In addition, formalin-fixed heart sections were stained with Trichrome and Aniline Blue to detect differences in collagen deposition and scar size. Using a light microscope (Axioskop2 equipped with AxioCam MRc5, Zeiss), Axio Vision 4.0 (Zeiss), and Adobe Photoshop CS3, the mean values of inflammatory infiltrate were determined within 3640 visual fields of each area of infarction. To evaluate the size of the infarction in relation to the area at risk (AAR) and left ventricle size, we performed 2,3,5-triphenyltetrazolium chloride (TTC) staining: The LAD was firmly re-occluded after 3 hours of reperfusion and 0.5 ml of Evan's blue was injected into the left ventricle. The presence of Evan's blue indicates perfusion, whereas its absence indicates lack of perfusion [31] . Sections from the left ventricles were put into a 2% TTC solution (Sigma) and stained for 15 minutes under constant shaking. Whereas brick red areas indicate viable myocardium, white regions demarcate tissue injury. Left ventricle size (LV), area at risk (AAR) and infarct area (Inf) were assessed by a blinded investigator. Measurements from multiple heart slices were averaged and Inf/AAR and AAR/LV calculated.
Echocardiography
Myocardial contractility was determined by transthoracic echocardiography using a sector scanner (AcuNav 10MHz, Acuson Sequoia C256, Acuson Corporation Mountain View, CA) and Visualsonics Vevo 770. Short-axis 2D-targeted M-mode images of the left ventricle were obtained. Fractional shortening (FS) was calculated from digital images by using a standard formula.
Bone Marrow Transplantation
Six to eight week-old recipient mice underwent a lethal totalbody irradiation (1000 Rad). Freshly isolated total host bone marrow cells were then injected into the lateral tail vein of syngenic recipient mice (5610 6 cells per mouse) 24 hours after irradiation. PCR analyses of blood cells and tail DNA indicated that ,95% of circulating leukocytes were of donor origin.
Preparation of Cardiac Samples and Immunoblot Analysis
Hearts were quickly removed and the area at risk from the left ventricle was immediately snap-frozen in liquid nitrogen. Proteins were extracted using T-PER Tissue Protein Extraction Reagent containing a Halt Protease and Phosphatase Inhibitor Cocktail (PIERCE, Rockford, USA). Protein extracts (20mg) were subjected to Western blot analysis with antibodies against phospho-ERK (T202/Y204, Cell Signaling), ERK (Cell Signaling), phospho-PLB (S16, Upstate), PLB (clone A1; Upstate), phospho-AKT (S473, R&D Systems), phospho-AKT (T308, Cell Signaling), and AKT (Cell Signaling). For Western blot analysis of PI3Kc, 40mg of protein was used.
Immunohistochemistry
Serial 5mm sections were cut from cryo-preserved tissue blocks, fixed in ice-cold acetone for 10 minutes and washed with TRIS buffer for 363 minutes. Sections were then blocked with MeOH and H 2 O 2 , washed with TRIS buffer, stained with a rabbit antibody against phospho-Akt (Ser473; R&D Systems) and subsequently counterstained with hematoxylin. 
